Home > Journals > Minerva Chirurgica > Past Issues > Minerva Chirurgica 2017 August;72(4) > Minerva Chirurgica 2017 August;72(4):317-33

CURRENT ISSUE
 

JOURNAL TOOLS

eTOC
To subscribe
Submit an article
Recommend to your librarian
 

ARTICLE TOOLS

Publication history
Reprints
Permissions
Cite this article as

 

REVIEW   

Minerva Chirurgica 2017 August;72(4):317-33

DOI: 10.23736/S0026-4733.17.07357-6

Copyright © 2017 EDIZIONI MINERVA MEDICA

language: English

The role of chemotherapy in unresectable or metastatic adenocarcinoma of the stomach and gastroesophageal junction

Mustafa BOZKURT, Fatemeh G. AMLASHI, Mariela BLUM MURPHY

Department of Gastrointestinal Medical Oncology, The University of Texas, MD Anderson Cancer Center, Houston, TX, USA


PDF


Gastric cancer including gastroesophageal junction adenocarcinomas are most challenging and deadly cancers of the gastrointestinal tract. Gastric cancer has a fatality-to-case ratio of 0.66, translating that nearly two thirds of newly diagnosed patients will have disseminated disease and in need of systemic therapy. Advanced gastric adenocarcinoma (AGC) is a heterogenous disease with differences in geographical distribution, histopathology, and molecular subtypes. Fluoropyrimidines (5-FU, S-1, and capecitabine), platinum compounds (cisplatin, oxaliplatin), taxanes (paclitaxel, docetaxel), and the topoisomerase inhibitory irinotecan are active drugs against AGC. The combination of fluoropyrimidines with a platinum compound is the optimal first-line treatment. Trastuzumab (given in combination with chemotherapy for HER2 positive tumors) and ramucirumab are the only targeted agents approved by the food and drug administration for the treatment in AGC for first and second line respectively. Efforts are being directed to harness the immune system with checkpoint inhibitors and to combining these drugs with chemotherapy in clinical trials. Genomic technology advancements might provide us with the tools to create personalized treatment for AGC in the near future with the goal to improve outcomes. In this article we aimed to review current therapeutic regimens for AGC with an update of ongoing clinical trials.


KEY WORDS: Stomach neoplasms - Esophagogastric junction - Drug Therapy - Molecular targeted therapy

top of page